Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Oncogene ; 26(42): 6220-8, 2007 Sep 13.
Article in English | MEDLINE | ID: mdl-17384672

ABSTRACT

Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN (which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT-PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.


Subject(s)
Chromosomes, Human, Pair 6/genetics , Neoplasms, Experimental/genetics , Utrophin/genetics , Animals , Base Sequence , Breast Neoplasms/genetics , Female , Humans , Male , Mammary Neoplasms, Experimental/genetics , Melanoma/genetics , Melanoma, Experimental/genetics , Mice , Mice, Nude , NIH 3T3 Cells , Neuroblastoma/genetics , Point Mutation , Sequence Deletion , Tumor Suppressor Proteins/biosynthesis , Tumor Suppressor Proteins/genetics , Utrophin/biosynthesis
2.
Diabetologia ; 48(11): 2236-40, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16195867

ABSTRACT

AIMS/HYPOTHESIS: Postprandial hypoglycaemia following gastric bypass for obesity is considered a late manifestation of the dumping syndrome and can usually be managed with dietary modification. We investigated three patients with severe postprandial hypoglycaemia and hyperinsulinaemia unresponsive to diet, octreotide and diazoxide with the aim of elucidating the pathological mechanisms involved. METHODS: Glucose, insulin, and C-peptide were measured in the fasting and postprandial state, and insulin secretion was assessed following selective intra-arterial calcium injection. Pancreas histopathology was assessed in all three patients. RESULTS: All three patients had evidence of severe postprandial hyperinsulinaemia and hypoglycaemia. In one patient, reversal of gastric bypass was ineffective in reversing hypoglycaemia. All three patients ultimately required partial pancreatectomy for control of neuroglycopenia; pancreas pathology of all patients revealed diffuse islet hyperplasia and expansion of beta cell mass. CONCLUSIONS/INTERPRETATION: These findings suggest that gastric bypass-induced weight loss may unmask an underlying beta cell defect or contribute to pathological islet hyperplasia, perhaps via glucagon-like peptide 1-mediated pathways.


Subject(s)
Gastric Bypass/adverse effects , Hypoglycemia/etiology , Hypoglycemia/surgery , Insulin/metabolism , Islets of Langerhans/pathology , Adult , Aged , Diazoxide/therapeutic use , Diet Therapy , Dumping Syndrome/etiology , Dumping Syndrome/pathology , Female , Humans , Hyperplasia , Hypoglycemia/diet therapy , Insulin Secretion , Islets of Langerhans/metabolism , Male , Middle Aged , Octreotide/therapeutic use , Pancreas/pathology , Pancreas/surgery , Pancreatectomy/methods
3.
Pediatr Dev Pathol ; 4(5): 434-45, 2001.
Article in English | MEDLINE | ID: mdl-11779045

ABSTRACT

Pleuropulmonary blastoma, an aggressive tumor that is emerging as a distinct entity of childhood, is characterized by mesenchymal elements (including undifferentiated blastema and often cartilaginous, rhabdomyoblastic, or fibroblastic differentiation) and epithelium-lined spaces. We investigated two patients with pleuropulmonary blastoma, a 3-year-old boy and an 11-year-old girl, both with large cystic masses replacing one lung. In both children, the post-chemotherapy resection specimens showed more maturation of rhabdomyoblasts and more nuclear pleomorphism in all mesenchymal cell lines, compared with biopsies sampled before treatment. Karyotypic analysis demonstrated gains in chromosome 8 in both cases and 17p deletion in one case. Fluorescent in situ hybridization analysis demonstrated that the chromosome 8 gains were present in all mesenchymal elements, including undifferentiated blastematous, rhabdomyoblastic, fibroblastic, and chondroblastic areas. Epithelial cells showed no chromosome 8 gains. The chromosome 8 aberrations were not appreciably different in pre- versus post-chemotherapy tissue. Our findings substantiate previous reports that polysomy of chromosome 8 is a consistent feature of pleuropulmonary blastoma. Further, they indicate that clonal proliferation in pleuropulmonary blastoma is restricted to the malignant mesenchymal elements, supporting the notion that the epithelial components of this tumor are non-neoplastic.


Subject(s)
Chromosome Aberrations , Chromosomes, Human, Pair 8 , Lung Neoplasms/genetics , Pulmonary Blastoma/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Child , Child, Preschool , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Immunoenzyme Techniques , In Situ Hybridization, Fluorescence , Karyotyping , Lung Neoplasms/chemistry , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Male , Pulmonary Blastoma/chemistry , Pulmonary Blastoma/therapy , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...